SCHEMBL3264723

SCHEMBL3264723

O=C(NCc1ccc(Cl)cc1)c1ccc(C(=O)N2CCCC(c3ccccc3)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
HIF1A Q16665 1/20 0.55
HSD11B1 P28845 2/20 0.52
MAPT P10636 2/20 0.52
GAA P10253 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ATM Q13315 1/20 0.51
PROKR1 Q8TCW9 7/20 0.51
TSHR P16473 1/20 0.50
CCR5 P51681 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394961 0.92 ALDH1A1 (0.61) ALDH1A1LMNAHPGDHIF1AHSD11B1
SCHEMBL3264724 0.88 ALDH1A1 (0.55) ALDH1A1LMNAHPGDHIF1AHSD11B1
SCHEMBL3262360 0.85 PROKR1 (0.46) ALDH1A1LMNAHPGDHIF1APROKR1
SCHEMBL3235156 0.84 MAPT (0.51) ALDH1A1MAPTGAAL3MBTL1
SCHEMBL3237604 0.84 GRM5 (0.68) ALDH1A1HPGDMAPTGAANPC1
SCHEMBL3259879 0.81 MAPT (0.70) ALDH1A1LMNAHPGDHSD11B1MAPT
SCHEMBL20394970 0.80 RAB9A (0.71) ALDH1A1MAPTGAANPC1RAB9A
SCHEMBL20394962 0.79 ALDH1A1 (0.61) ALDH1A1LMNAHPGDHIF1AHSD11B1
SCHEMBL3236002 0.79 GRM5 (0.58) ALDH1A1LMNAHPGDHSD11B1MAPT
SCHEMBL20394972 0.79 GAA (0.63) ALDH1A1LMNAHPGDMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 ALDH1A1 1588/4885LMNA 1683/4885HPGD 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.